Table 5 Association between patient background and occurrence of infections, PGA response, and reduction in ocular attacks
Infections | PGA response | Reduction in ocular attacks | |||||||
|---|---|---|---|---|---|---|---|---|---|
All | Occurred | p a | Allb | Response ratec | p a | Alld | Absence of ocular attackse | p a | |
n | n (%) | n | n (%) | n | n (%) | ||||
All patients | 656 | 78 (11.89) | – | 623 | 503 (80.7) | – | 506 | 217 (42.9) | – |
Disease duration of BD, years | |||||||||
< 5 | 268 | 25 (9.33) | 0.130 | 255 | 216 (84.7) | 0.008 | 212 | 88 (41.5) | 0.216 |
≥ 5–< 10 | 159 | 17 (10.69) | 153 | 128 (83.7) | 129 | 62 (48.1) | |||
≥ 10–< 15 | 95 | 17 (17.89) | 88 | 70 (79.5) | 73 | 24 (32.9) | |||
≥ 15 | 77 | 11 (14.29) | 74 | 50 (67.6) | 55 | 23 (41.8) | |||
unknown | 57 | 8 (14.04) | 53 | 39 (73.6) | 37 | 20 (54.1) | |||
Disease duration of uveitis, years | |||||||||
< 5 | 294 | 28 (9.52) | 0.080 | 274 | 234 (85.4) | 0.030 | 234 | 99 (42.3) | 0.011 |
≥ 5–< 10 | 166 | 19 (11.45) | 162 | 132 (81.5) | 130 | 70 (53.8) | |||
≥ 10–< 15 | 86 | 17 (19.77) | 82 | 66 (80.5) | 71 | 22 (31.0) | |||
≥ 15 | 60 | 7 (11.67) | 58 | 40 (69.0) | 41 | 15 (36.6) | |||
unknown | 50 | 7 (14.00) | 47 | 31 (66.0) | 30 | 11 (36.7) | |||
Severity of ocular symptoms | |||||||||
severe | 408 | 53 (12.99) | 0.342 | 390 | 326 (83.6) | < 0.001 | 332 | 125 (37.7) | 0.007 |
moderate | 201 | 18 (8.96) | 193 | 157 (81.3) | 154 | 81 (52.6) | |||
mild | 36 | 4 (11.11) | 33 | 18 (54.5) | 14 | 7 (50.0) | |||
unknown | 11 | 3 (27.27) | 7 | 2 (28.6) | 6 | 4 (66.7) | |||
History of allergic disease | |||||||||
no | 618 | 69 (11.17) | 0.034 | 586 | 472 (80.5) | 0.830 | 480 | 206 (42.9) | 1.000 |
yes | 38 | 9 (23.68) | 37 | 31 (83.8) | 26 | 11 (42.3) | |||
Extraocular symptoms of BD | |||||||||
oral aphthous ulcersf | |||||||||
no | 117 | 11 (9.40) | 0.432 | 112 | 81 (72.3) | 0.016 | 82 | 34 (41.5) | 0.808 |
yes | 534 | 66 (12.36) | 506 | 419 (82.8) | 421 | 182 (43.2) | |||
skin lesionsf | |||||||||
no | 259 | 30 (11.58) | 0.902 | 245 | 186 (75.9) | 0.012 | 197 | 76 (38.6) | 0.118 |
yes | 392 | 47 (11.99) | 373 | 314 (84.2) | 306 | 140 (45.8) | |||
central nervous system lesionsf | |||||||||
no | 587 | 68 (11.58) | 0.542 | 559 | 463 (82.8) | 0.001 | 460 | 197 (42.8) | 0.873 |
yes | 64 | 9 (14.06) | 59 | 37 (62.7) | 43 | 19 (44.2) | |||
intestinal tract lesionsf | |||||||||
no | 584 | 67 (11.47) | 0.423 | 557 | 460 (82.6) | 0.003 | 471 | 200 (42.5) | 0.462 |
yes | 67 | 10 (14.93) | 61 | 40 (65.6) | 32 | 16 (50.0) | |||
Comorbidity | |||||||||
respiratory disease | |||||||||
no | 646 | 74 (11.46) | 0.022 | 614 | 497 (80.9) | 0.385 | 500 | 215 (43.0) | 0.704 |
yes | 10 | 4 (40.00) | 9 | 6 (66.7) | 6 | 2 (33.3) | |||
cardiac disease | |||||||||
no | 646 | 76 (11.76) | 0.338 | 616 | 500 (81.2) | 0.029 | 499 | 213 (42.7) | 0.469 |
yes | 10 | 2 (20.00) | 7 | 3 (42.9) | 7 | 4 (57.1) | |||
diabetes mellitus | |||||||||
no | 625 | 74 (11.84) | 0.778 | 593 | 486 (82.0) | 0.002 | 486 | 214 (44.0) | 0.010 |
yes | 31 | 4 (12.90) | 30 | 17 (56.7) | 20 | 3 (15.0) | |||
Concomitant drug | |||||||||
cyclosporine | |||||||||
no | 443 | 48 (10.84) | 0.247 | 418 | 338 (80.9) | 0.914 | 332 | 158 (47.6) | 0.003 |
yes | 213 | 30 (14.08) | 205 | 165 (80.5) | 174 | 59 (33.9) | |||
glucocorticoids | |||||||||
no | 124 | 10 (8.06) | 0.167 | 114 | 101 (88.6) | 0.018 | 93 | 43 (46.2) | 0.488 |
yes | 532 | 68 (12.78) | 509 | 402 (79.0) | 413 | 174 (42.1) | |||